Cytodyn featured in this blog for emerging biotech
Post# of 153986
(Total Views: 796)
Posted On: 12/08/2020 10:18:24 AM
Cytodyn featured in this blog for emerging biotechs for HIV.
https://www.startus-insights.com/innovators-g...-diseases/
CytoDyn – Antiviral Agents For HIV
Despite recent advancements in the availability of lifelong antiretroviral therapy (ART) for HIV autoimmune deficiency syndrome (AIDS), several people still cannot access suitable treatment. Current medication for HIV/AIDS works to prevent viral transmission while helping individual immune systems. With increasing investments, emerging pharma startups are developing novel solutions to fight, and eventually eliminate, HIV/AIDS.
The US-based startup Cytodyn is developing Leronlimab (PRO 140), a new class of HIV/AIDS antiviral agents that protect healthy cells from viral infection. This self-injectable, subcutaneous injection for HIV offers advantages over the current treatments that include no serious side effects and serious adverse events (SAEs) related to Leronlimab. In addition, this solution enables enhanced compliance and increases its half-life. Leronlimab is currently awaiting US Food and Drug Administration (FDA) approval, after completing Phase 3 clinical trials.
https://www.startus-insights.com/innovators-g...-diseases/
CytoDyn – Antiviral Agents For HIV
Despite recent advancements in the availability of lifelong antiretroviral therapy (ART) for HIV autoimmune deficiency syndrome (AIDS), several people still cannot access suitable treatment. Current medication for HIV/AIDS works to prevent viral transmission while helping individual immune systems. With increasing investments, emerging pharma startups are developing novel solutions to fight, and eventually eliminate, HIV/AIDS.
The US-based startup Cytodyn is developing Leronlimab (PRO 140), a new class of HIV/AIDS antiviral agents that protect healthy cells from viral infection. This self-injectable, subcutaneous injection for HIV offers advantages over the current treatments that include no serious side effects and serious adverse events (SAEs) related to Leronlimab. In addition, this solution enables enhanced compliance and increases its half-life. Leronlimab is currently awaiting US Food and Drug Administration (FDA) approval, after completing Phase 3 clinical trials.
(1)
(0)